- Home
- ICCM vs MRSN Comparison
ICCM vs MRSN Comparison
Compare ICCM & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICCM
- MRSN
- Stock Information
- Founded
- ICCM 2006
- MRSN 2001
- Country
- ICCM Israel
- MRSN United States
- Employees
- ICCM N/A
- MRSN N/A
- Industry
- ICCM
- MRSN Biotechnology: Pharmaceutical Preparations
- Sector
- ICCM
- MRSN Health Care
- Exchange
- ICCM Nasdaq
- MRSN Nasdaq
- Market Cap
- ICCM 72.4M
- MRSN 74.8M
- IPO Year
- ICCM N/A
- MRSN 2017
- Fundamental
- Price
- ICCM $1.21
- MRSN $0.54
- Analyst Decision
- ICCM Strong Buy
- MRSN Buy
- Analyst Count
- ICCM 2
- MRSN 6
- Target Price
- ICCM $2.70
- MRSN $6.00
- AVG Volume (30 Days)
- ICCM 441.2K
- MRSN 7.3M
- Earning Date
- ICCM 11-26-2024
- MRSN 02-26-2025
- Dividend Yield
- ICCM N/A
- MRSN N/A
- EPS Growth
- ICCM N/A
- MRSN N/A
- EPS
- ICCM N/A
- MRSN N/A
- Revenue
- ICCM $3,671,000.00
- MRSN $34,837,000.00
- Revenue This Year
- ICCM $10.03
- MRSN N/A
- Revenue Next Year
- ICCM $62.68
- MRSN N/A
- P/E Ratio
- ICCM N/A
- MRSN N/A
- Revenue Growth
- ICCM 26.02
- MRSN N/A
- 52 Week Low
- ICCM $0.48
- MRSN $0.55
- 52 Week High
- ICCM $1.57
- MRSN $6.28
- Technical
- Relative Strength Index (RSI)
- ICCM 60.15
- MRSN 19.11
- Support Level
- ICCM $1.16
- MRSN $0.56
- Resistance Level
- ICCM $1.27
- MRSN $0.63
- Average True Range (ATR)
- ICCM 0.10
- MRSN 0.13
- MACD
- ICCM -0.02
- MRSN -0.04
- Stochastic Oscillator
- ICCM 41.64
- MRSN 0.98
About ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.